Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.
Kidney cancer (KC) is an important public-health challenge in China. Although benmelstobart plus anlotinib (BEN + AL) improves survival compared with sunitinib (SUN) for advanced renal cell carcinoma, its economic value in the Chinese healthcare system remains uncertain. Epidemiological trends in KC...
| Publicado en: | Inquiry (00469580) Vol. 63; pp. 1 - 18 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
4/9/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |